. 2022 Nov 29;33(4):607–618. doi: 10.1136/ijgc-2022-003719

Table 6.

Combinations of immunotherapy with anti-angiogenic agents for the treatment of recurrent ovarian cancer

Trial name/identification	Phase	Treatment(s)	Disease setting	Sample size	Follow-up (median months)	Objective response rate (%)	Progression-free survival (median months)	Overall survival (median months)
Lee et al. 2017⁵⁴	I	Durvalumab+ cediranib	Recurrent platinum-sensitive/resistant ovarian cancer	26	Not reported	50%	Not reported	Not reported
Liu et al. 2019⁵⁵	II	Nivolumab+ bevacizumab	Relapsed platinum-sensitive/resistant ovarian cancer	38	Not reported	28.9%	8.1	Not reported
LEAP 005 (González-Martín et al. 2020)⁵⁶	II	Lenvatinib+ pembrolizumab	Previously treated ovarian cancer	31	7.8	32%	4.4	Not reported
EORTC-1508 (Banerjee et al. 2021)⁵⁷	II	Atezolizumab+ bevacizumab (±acetylsalicylic acid) vs bevacizumab vs atezolizumab vs atezolizumab+ acetylsalicylic acid	Recurrent platinum-resistant ovarian cancer	122	Not reported	15.2% atezolizumab+ bevacizumab + acetylsalicylic acid 19.4% atezolizumab+ bevacizumab 9.7% bevacizumab	4.0 atezolizumab+ bevacizumab + acetylsalicylic acid 4.1 atezolizumab+ bevacizumab 2.3 bevacizumab 2.1 atezolizumab 2.2 atezolizumab+ acetylsalicylic acid	11.6 atezolizumab+ bevacizumab + acetylsalicylic acid 12.1 atezolizumab+ bevacizumab 10.4 bevacizumab